Bristol Myers Squibb (NYSE:BMY) Issues FY 2026 Earnings Guidance

Bristol Myers Squibb (NYSE:BMY) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 6.750-7.000 for the period, compared to the consensus estimate of 6.310. The company issued revenue guidance of $49.0 billion-$50.0 billion, compared to the consensus revenue estimate of $47.3 billion.

Bristol Myers Squibb Stock Up 0.9%

Bristol Myers Squibb stock opened at $65.44 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The company has a fifty day simple moving average of $58.02 and a 200 day simple moving average of $58.34. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $65.66. The company has a market cap of $133.62 billion, a P/E ratio of 14.41, a price-to-earnings-growth ratio of 0.18 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 69.75% and a net margin of 18.87%.The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same period in the previous year, the firm earned $1.46 EPS. The firm’s revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts anticipate that Bristol Myers Squibb will post 6.34 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Raymond James Financial reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Bank of America decreased their price objective on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. Finally, Weiss Ratings upgraded shares of Bristol Myers Squibb from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday. Nine research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $63.24.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Strong Q2 results and raised guidance: Bristol Myers reported adjusted EPS of $2.04 versus the $1.60 consensus and revenue of $12.97 billion versus expectations of $11.74 billion. Revenue rose 5.7% year over year. Management raised 2026 EPS guidance to $6.75-$7.00 and revenue guidance to $49-$50 billion, both above Wall Street estimates. Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results
• Positive Sentiment: Growth products are gaining momentum: Eliquis sales, along with newer medicines including Camzyos, Reblozyl, Opdivo Qvantig and Breyanzi, drove results. The growth portfolio now contributes roughly 60% of revenue, helping offset pressure from older products. Bristol-Myers Squibb Q2 2026 earnings call transcript
• Positive Sentiment: Several analysts raised targets: JPMorgan lifted its target from $67 to $73 and maintained an “overweight” rating, while Truist raised its target from $65 to $70 and reaffirmed “buy.” These revisions suggest analysts see additional upside following the earnings beat.
• Neutral Sentiment: Valuation is back in focus: Analysts note that BMY’s strong performance and recent rally have reduced the margin of safety, despite relatively attractive valuation and dividend support. RBC raised its target to $64 but retained a “sector perform” rating, implying the shares may remain range-bound. Bristol-Myers Squibb’s Catalyst Delays May Keep Stock Range-Bound, RBC Says
• Negative Sentiment: Pipeline timing and legacy declines remain risks: Delayed readouts or launches for Milvexian and Cobenfy, along with declines in older medicines such as Opdivo, could temper the growth outlook and postpone upcoming catalysts.
• Negative Sentiment: Bearish options activity: Traders purchased 44,620 put options, about 77% above typical daily volume, signaling increased hedging or speculation on downside risk.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Sunbelt Securities Inc. raised its position in Bristol Myers Squibb by 7.1% in the fourth quarter. Sunbelt Securities Inc. now owns 13,313 shares of the biopharmaceutical company’s stock worth $718,000 after acquiring an additional 878 shares during the period. Compound Planning Inc. lifted its position in Bristol Myers Squibb by 104.4% during the fourth quarter. Compound Planning Inc. now owns 23,633 shares of the biopharmaceutical company’s stock valued at $1,275,000 after purchasing an additional 12,072 shares in the last quarter. TMB Capital Partners LLC bought a new stake in Bristol Myers Squibb during the fourth quarter valued at about $356,000. Axxcess Wealth Management LLC increased its position in Bristol Myers Squibb by 3.2% in the fourth quarter. Axxcess Wealth Management LLC now owns 79,944 shares of the biopharmaceutical company’s stock worth $4,312,000 after buying an additional 2,475 shares in the last quarter. Finally, Birchwood Financial Partners Inc. bought a new position in shares of Bristol Myers Squibb in the fourth quarter worth about $50,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.